Discover key insights into the Onychomycosis market in DelveInsight's detailed report @Onychomycosis market size
Key Takeaways from the Onychomycosis Market Report
- The total prevalence of onychomycosis in the United States was approximately 37.25 million in 2023. These cases are expected to change significantly by 2034.
- Among the epidemic cases of onychomycosis classified by severity in Germany in 2023, moderate cases accounted for the largest proportion, totalling around 726,000 cases. These figures are expected to fluctuate from 2024 to 2034.
- In the UK, categorization of onychomycosis cases by subtype showed a higher prevalence of distal subungual onychomycosis compared to superficial white onychomycosis, proximal subungual onychomycosis, and candidal onychomycosis. Approximately 861,000 cases of distal subungual onychomycosis will be recorded in 2023, with further variation expected throughout the forecast period (2020-2034).
- In France, approximately 11,465,000 epidemic cases of onychomycosis were recorded in 2023. These cases are predicted to change by 2034.
- The number of patients with onychomycosis diagnosed as prevalent in Japan in 2023 was approximately 2,296,000. This figure is expected to fluctuate further by 2034.
- In Japan, moderate onychomycosis was the most common severity category, with approximately 916,000 patients in 2023, followed by severe cases, with mild onychomycosis accounting for the lowest proportion.
- A leading company in onychomycosis includes Moberg Pharma, Blueberry Therapeutics, Hallux, Pfizer, Bausch Health, Sato Pharmaceutica, and Eisai.
- A promising treatment for onychomycosis includes Keridine (tavaborole), Jubria/Clenafin (efinaconazole), BB2603, and VT-1161.
Get an edge in the Onychomycosis Treatments market with DelveInsight's strategic report @Onychomycosis Market Outlook
Epidemiological segmentation of onychomycosis in the 7MM
- Total number of people with onychomycosis
- Total diagnosed cases of onychomycosis
- Prevalent cases of onychomycosis diagnosed with subtype specificity
- Prevalent cases of onychomycosis diagnosed by severity
Download the report to understand what factors are driving epidemiological trends in onychomycosis. @Prevalence of Onychomycosis
Over-the-counter treatments for nail fungus
Kerizin (tavaborole): Pfizer
KERYDIN (tavaborol) topical solution contains 5% (w/w) tavaborol in a clear, colorless, alcohol-based solution for topical use. Tavaborol, an oxaborole antifungal drug, is a white to off-white powder that is slightly soluble in water and freely soluble in ethanol and propylene glycol. KERYDIN contains 43.5 mg of tavaborol per mL of solution. Inactive ingredients include alcohol, edetate calcium disodium, and propylene glycol.
JUBLIA/CLENAFIN (efinaconazole): Bausch Health
Efinaconazole 10% nail solution (JUBLIA) is a new topical triazole antifungal agent designed to treat distal and lateral subungual onychomycosis. Efinaconazole has a lower minimum inhibitory concentration than terbinafine, ciclopirox, itraconazole, and amorolfine.Trichophyton rubrum、 Tinea fungus, and Candida. The solution-based formula has low surface tension and keratin-binding properties, enhancing penetration into the nail plate. Safety studies have shown that the formulation does not cause atopic dermatitis or contact hypersensitivity. Efinaconazole 10% Nail Solution is a safe and effective new topical therapy for onychomycosis, addressing the need for improved treatment options. It is marketed under the brand names JUBLIA in the United States and CLENAFIN in Japan.
New Treatment for Onychomycosis
BB2603: Blueberry Therapeutics
Blueberry Therapeutics' squalene epoxidase inhibitor, BB2603, is formulated as a spray and is currently in Phase I/II trials for the treatment of onychomycosis and the related tinea pedis. BB2603 employs nanotechnology to deliver terbinafine, a potent antifungal drug, through the nail to the skin to effectively treat fungal infections.
VT-1161: Mycovia Pharmaceuticals
VT-1161 is a potent, selective, oral inhibitor of fungal CYP51. In vitro and in vivo studies have demonstrated Candida includes species and dermatophytesTrichophyton rubrum and Tinea fungus, which are the main cause of onychomycosis. VT-1161's high selectivity against fungal CYP51 is expected to reduce the side effects commonly associated with antifungal drugs such as fluconazole, itraconazole, posaconazole, terbinafine, and voriconazole.
For more information on nail fungus treatment guidelines, please visit @Outlook for the Onychomycosis Treatment Market
Onychomycosis Market Outlook
Onychomycosis is a fungal infection that primarily affects the nail bed and is often referred to as "toenail fungus" because toenail infections account for the majority of cases. Nail disease is one of the most common foot conditions for which adults seek over-the-counter medications and medical help. The infection usually begins as small white or yellow spots under the nail plate and progresses to discoloration, thickening, and cracking of the nail. It is estimated that approximately 3% of the general adult population is affected by the disease, and approximately 20% of individuals between the ages of 40 and 60 are affected.
Scope of the Onychomycosis Market Report
- coverage: 7MM
- Study period: 2020–2034
- Claw Fungus Disease Enterprise: Moberg Pharma, Blueberry Therapeutics, Hallux, Pfizer, Bausch Health, Sato Pharmaceutical, Eisai, etc.
- Treatment for Onychomycosis: KERYDIN (tavaborole), JUBLIA/CLENAFIN (efinaconazole), BB2603, VT-1161, etc.
- Dynamics of the Onychomycosis MarketMarket drivers and barriers
- Onychomycosis Market Access and Reimbursement, Unmet Needs, and Future Outlook
Learn more about drugs in development for treating onychomycosis @Clinical Trial Evaluation of Onychomycosis
table of contents
- Key Insights
- Report Overview
3 Overview of the Onychomycosis Market
4 Overview of Onychomycosis
- Background and overview of the disease
6 Treatment of Onychomycosis
7 Management of Onychomycosis
8 Guidelines
8.1 British Association of Dermatologists (BAD) guidelines for the management of onychomycosis
9 Epidemiology and prevalence
- The Patient Journey
11 Commercial products
12 new treatments
13 Onychomycosis: 7 major markets
Opinions of 14 key opinion leaders
15 SWOT Analysis
16 Unmet Needs
17 Market Access and Reimbursement
18 Appendix
19 DelveInsight Features
20 Disclaimer
21 About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm, providing clients with high-quality market intelligence and analytics to support informed business decisions. With an experienced team of industry experts and a deep understanding of the life sciences and healthcare sector, we deliver customized research solutions and insights to clients globally. Contact us to get high-quality, accurate, real-time intelligence to stay ahead of the growth curve.
Contact Information:
Himanshu
humason@delveinsight.com
info@delveinsight.com
+14699457679
